SCHEMBL564199

SCHEMBL564199

Cc1cccc(CN2CCOC(C(=O)N(Cc3cc(Cl)c4c(c3)OCCCO4)CC(C)C)C2)c1C

nearest known ligand 0.74

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PROKR2 Q8NFJ6 5/20 0.74
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
HPGD P15428 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
HSD17B10 Q99714 1/20 0.36
GRN P28799 1/20 0.34
SORT1 Q99523 1/20 0.34
ACKR3 P25106 1/20 0.34
DRD4 P21917 1/20 0.34
PDCD1 Q15116 6/20 0.32
CD274 Q9NZQ7 6/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2D6 P10635 1/20 0.32
CYP2C19 P33261 1/20 0.32
GRIN2B Q13224 2/20 0.32
S1PR1 P21453 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL565706 0.95 PROKR2 (0.75) PROKR2KDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL565611 0.89 PROKR2 (0.73) PROKR2KDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL565016 0.89 PROKR2 (0.69) PROKR2KDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL565721 0.89 PROKR2 (0.75) PROKR2KDM4EPDCD1CD274S1PR1
SCHEMBL10106691 0.89 PROKR2 (0.75) PROKR2KDM4EPDCD1CD274S1PR1
SCHEMBL565513 0.89 PROKR2 (0.76) PROKR2KDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL564802 0.88 PROKR2 (0.75) PROKR2KDM4EALDH1A1SMN1; SMN2PDCD1
SCHEMBL10107322 0.88 PROKR2 (0.75) PROKR2KDM4EALDH1A1SMN1; SMN2PDCD1
SCHEMBL10107537 0.88 PROKR2 (0.73) PROKR2KDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL20936053 0.88 PROKR2 (0.77) PROKR2KDM4EALDH1A1DRD4PDCD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722896-B2 Prokineticin receptor antagonists and uses thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-05-13 US disclosed
US-8722896-B2 Prokineticin receptor antagonists and uses thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-05-13 US disclosed
US-8722896-B2 Prokineticin receptor antagonists and uses thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-05-13 US disclosed
US-20120035149-A1 Prokineticin Receptor Antagonists And Uses Thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-02-09 US disclosed
US-20120035149-A1 Prokineticin Receptor Antagonists And Uses Thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-02-09 US disclosed
US-20120035149-A1 Prokineticin Receptor Antagonists And Uses Thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120035149-A1 Prokineticin Receptor Antagonists And Uses Thereof PROKR2, PROKR1, GIPR PROKR2 1/4885KDM4E 4874/4885ALDH1A1 4725/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.